Amarantus BioScience to Hold Business Update Conference Call on April 16
Amarantus BioScience to Hold Business Update Conference Call on April 16
SUNNYVALE, Calif.--(BUSINESS WIRE)-- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it will hold a conference call on Tuesday, April 16, 2013 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to provide an update on its business and conduct a question and answer session with investors.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033, or for international callers 201-689-8033. The call is also being webcast, and can be accessed from the Company's Web site (www.amarantus.com) and at www.InvestorCalendar.com.
A telephone replay will be available through May 1, 2013 by dialing 877-660-6853, or for international callers 201-612-7415, and entering the Conference ID #: 411612. The webcast replay will be available for 90 days following the completion of the call.
During the call Amarantus Chief Executive Officer Gerald Commissiong will recap key accomplishments of 2012 and the first quarter of 2013, provide clarity on the Company's recently updated business model and discuss business and product development initiatives planned for the remainder of 2013.
About Amarantus BioScience
Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for neurological disorders where there is a significant unmet medical need. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and related nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson's disease, as well as statements about expectations, plans and prospects of the development of Amarantus' diagnostic product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Investor/Media Contact
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com
KEYWORDS: United States North America California
INDUSTRY KEYWORDS:
The article Amarantus BioScience to Hold Business Update Conference Call on April 16 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
